Compare · DXCM vs NPCE
DXCM vs NPCE
Side-by-side comparison of DexCom Inc. (DXCM) and Neuropace Inc. (NPCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NPCE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $40.07B, about 198.5x NPCE ($201.8M).
- Over the past year, DXCM is down 13.5% and NPCE is up 44.9% - NPCE leads by 58.4 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 3 for NPCE).
- DXCM has more recent analyst coverage (25 ratings vs 15 for NPCE).
- Company
- DexCom Inc.
- Neuropace Inc.
- Price
- $61.55-1.84%
- $16.84-0.09%
- Market cap
- $40.07B
- $201.8M
- 1M return
- -7.89%
- +25.26%
- 1Y return
- -13.51%
- +44.94%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 15
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest NPCE
- SEC Form DEFA14A filed by Neuropace Inc.
- SEC Form DEF 14A filed by Neuropace Inc.
- NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 4 filed by Morrell Martha
- SEC Form 4 filed by Geiger Uri
- SEC Form 4 filed by Lacob Joseph
- SEC Form 4 filed by Kumar Rakhi
- SEC Form 4 filed by Fischer Frank M
- NeuroPace to Present at the Leerink Global Healthcare Conference
- CHIEF MEDICAL OFFICER Morrell Martha sold $399,250 worth of shares (25,000 units at $15.97) and covered exercise/tax liability with 1,340 shares, decreasing direct ownership by 35% to 48,624 units (SEC Form 4)